Since its establishment, Kanghong Pharmaceutical has been recognized by governments at all levels and society. The Kanghong trademark is a well-known trademark in China; in 2006, Kanghong Pharmaceutical was named "Industrial Enterprise with Outstanding Contribution in Sichuan Province"; in 2007 It was included in the provincial and municipal government's "Large Enterprises and Groups" cultivation list; in 2008, Kanghong was awarded the "Enterprise Credit Rating AAA Credit Enterprise"; in 2009, it was awarded the "China Pharmaceutical 30 Years Summit" and "Reform and Opening Up Three Years". Ten Years of Innovation Award"; in 2010, it was included in the "National Enterprises and Institutions Intellectual Property Pilot Units"; in 2011, it was named "Top Ten Innovative Enterprise Brands in China's Chemical Pharmaceutical Industry".
Since its establishment, Kanghong Pharmaceutical has been based on a professional and innovative development strategy led by product and technological innovation, guided by clinical needs, in-depth research, professional innovation, and professional services in core therapeutic areas. . Create a six-in-one systematic and standardized operating profit model of "focused areas - demand orientation - in-depth research - patented new drugs - standardized production - professional marketing". In key technical fields, innovative technologies based on the "Kanghong Postdoctoral Research Workstation", "Nationally Recognized Enterprise Technology Center", and "Sichuan Provincial Key Laboratory of Biomacromolecule Protein Drugs" have been fully formed. Kanghong Pharmaceutical's corporate technology center has established a number of technology platforms related to Chinese patent medicines, chemical drugs, and biological products, including protein drug engineering technology platform, gene therapy R&D technology platform, drug industrialization technology platform, drug screening and pharmaceutical Effectiveness evaluation technology platform, traditional Chinese medicine natural medicine pilot research technology platform, new pharmaceutical preparation research technology platform, bioinformatics research technology platform, etc. to meet the research and development needs of various new drugs. At present, Kanghong Pharmaceutical's product group has covered the central nervous system, digestion, ophthalmology and other treatment fields. It has applied for and authorized more than 100 patents (including more than 20 foreign patents), and has undertaken 10 national-level projects; 3 national "major new drugs" "Creation" major science and technology project, three national 863 plan projects, one national "973" plan project, one National Development and Reform Commission enterprise technology center innovation capacity building project, one scientific and technological personnel service enterprise action project, one National Development and Reform Commission high-tech industry chemical projects and more than 30 key scientific and technological projects in Sichuan Province and Chengdu City.
According to the "Chengdu Municipal Party Committee Document No. 19", the Chengdu Municipal Party Committee and the Municipal Government have listed "KH series of biotech drugs" as Chengdu's "strategic emerging products" and provided support for key projects. Among them, Conbercept, a Class I new drug for the treatment of fundus diseases, has entered the Phase III clinical stage and is expected to be the first to be launched in China by the end of 2012, bringing good news to many patients in China.
Among Kanghong's R&D and innovation achievements, there are currently 11 marketed varieties, 10 of which are "national medical insurance products": "Songling Xuemaikang Capsules" are national essential drugs and national prescription invention patented drugs. , a famous brand product in Sichuan Province, and together with "Yiqing Capsule" and "Zhenke Ning Capsule" are national protected varieties of traditional Chinese medicine. "Songling Xuemaikang Capsule" is a basic medicine for treating high blood pressure and preventing and treating stroke; "Yiqing Capsule" is a classic medicine for treating "pyretic syndrome". It is also a recommended medicine in "Otorhinolaryngology-Head and Neck Surgery" and is recommended by Sichuan Province. Famous brand product; "Zhenke Ning Capsule" is a pure Chinese medicine preparation that is antitussive and expectorant and does not contain codeine. The biliary system medication "Danshu Capsule" has a unique dual choleretic pathway and is a natural botanical medicine that repairs biliary motility disorders. It is Kanghong's exclusive product and has won the gold medal at the National Spark Technology Exhibition and the Chengdu Excellent New Product Award. "Ganke Shuangqing Capsule" is a highly effective plant monomer drug specially used for the treatment of upper respiratory tract infections and acute bronchitis. The marketed SNRI antidepressant drug "Bolexin" and DSS antipsychotic drug "Bosiqing", as well as the digestive tract prokinetic drug "Xinluona" have been included in the National Torch Plan projects. The Chinese patent medicine "Shugan Jieyu Capsule" for treating mild to moderate depression and the Chinese patent medicine "Keluoxin Capsule" for treating diabetic nephropathy are both "National Prescription Invention Patented Drugs". In 2010, Kanghong launched a new generation of sedative-hypnotic drug "Etanine-eszopiclone tablets".
Kanghong not only builds the company's core advantages through the research and development of patented new drugs, but also regards product quality as the life of the company.
It is precisely because of the continuous pursuit of "perfection" of drug quality that Kanghong worked closely with the American Sagent Holding Co. in 2006 to jointly invest in the establishment of Kanghong Sagent (Chengdu) Pharmaceuticals Ltd. The joint venture will be built in accordance with U.S. cGMP standards and will pass U.S. FDA certification. As the group's export preparation production base, Kanghong Saijin (Chengdu) Pharmaceutical Co., Ltd. has a world-leading fully enclosed injection production line. The production line has been fully installed and is expected to be officially put into production in 2012.
In order to ensure the quality of Chinese patent medicine products, Kanghong starts from the source of Chinese medicinal materials. In 2011, Kanghong officially invested in the construction of a GAP base in Fushun County, Zigong City. Relying on the construction of a national key masson pine improved seed base in Fushun Forestry Farm, Kanghong will provide stable and uniform quality Chinese medicinal materials for the national essential drug "Songling Xuemaikang Capsules" exclusively produced by the group. raw material.